Table 5.
Impact of artificial sweeteners long-term consumption among type 2 diabetic patients.
| Variables | Duration of Sweetener Consumption ≥1 Tablet/Day in Diabetic Patients |
p * Value |
||
|---|---|---|---|---|
| <5 Years | 5–10 Years | >10 Years | ||
| (N = 49) | (N = 29) | (N = 10) | ||
| WC (cm) | 106.35 ± 10.89 | 103.34 ± 7.9 | 106.7 ± 9.35 | NS |
| BMI (Kg/m2) | 32.42 ± 4.93 | 30.71 ± 4.39 | 30.61 ± 4.9 | NS |
| Systolic BP (mm Hg) | 138.55 ± 16.49 | 140.72 ± 16.27 | 141.5 ± 19.73 | NS |
| Diastolic BP (mm Hg) | 86.94 ± 7.89 | 85.34 ± 6.4 | 84.50 ± 8.32 | NS |
| FSG (mg/dL) | 211.82 ± 81.87 | 228.38 ± 77.54 | 263.6 ± 75.37 | NS |
| HbA1c (%) | 8.07 ± 1.74 | 8.65 ± 1.77 | 8.8 ± 1.19 | NS |
| ALT (IU/L) | 13.55 ± 4.43 | 12.22 ± 5.24 | 11.86 ± 3.32 | NS |
| Creatinine (mg/dL) | 0.84 ± 0.21 | 0.84 ± 0.22 | 0.84 ± 0.16 | NS |
| Total Cholesterol (mg/dL) | 188.2 ± 42.47 | 174.62 ± 47.54 | 207.5 ± 39.29 | NS |
| Triglyceride (mg/dL) | 164.9 ± 77.91 | 158.86 ± 91.42 | 245.7 ± 145.84 | 0.03 |
| HDL (mg/dL) | 40.33 ± 9.39 | 44 ± 14.96 | 36.8 ± 8.95 | NS |
| LDL (mg/dL) | 111.82 ± 35.76 | 97.67 ± 37.83 | 129.72 ± 37.72 | 0.049 |
| TC/HDL | 4.88 ± 1.43 | 4.38 ± 1.95 | 6.05 ± 2.22 | 0.033 |
| MDA (nmole/mL) | 2.37 ± 0.60 | 2.26 ± 0.40 | 2.21 ± 0.59 | NS |
| Ceruloplasmin (mg/mL) | 27.74 ± 9.11 | 28.10 ± 10.10 | 23.87 ± 5.6 | NS |
| Peroxynitrite (mmole/L) | 1.67 ± 0.61 | 1.58 ± 0.59 | 1.86 ± 0.60 | NS |
| Catalase (kU/L) | 9.37 ± 2.51 | 8.52 ± 2.79 | 8.44 ± 2.12 | NS |
The evaluation of the impact of artificial sweetener long-term consumption among type 2 diabetic patients was performed by comparing patients who consumed sweeteners for 1–4 years, 5–10 years, and more than 10 years. The comparison was performed using one-way ANOVA. Values presenting p > 0.05 were considered non-significant (NS).